These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506 [TBL] [Abstract][Full Text] [Related]
44. [Treatment of plaque psoriasis with an aromatic retinoid (etretinate)]. Melis M Rev Med Chil; 1984 Jan; 112(1):20-5. PubMed ID: 6377426 [No Abstract] [Full Text] [Related]
45. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Van Joost T; Bos JD; Heule F; Meinardi MM Br J Dermatol; 1988 Feb; 118(2):183-90. PubMed ID: 3280000 [TBL] [Abstract][Full Text] [Related]
46. Fucidin in psoriasis. A double-blind study of twenty psoriatics over two periods of four weeks each. Nyfors A Dermatologica; 1973; 146(5):281-4. PubMed ID: 4583782 [No Abstract] [Full Text] [Related]
47. Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study. Parrish JA; White AD; Kingsbury T; Zahar M; Fitzpatrick TB Arch Dermatol; 1977 Nov; 113(11):1529-32. PubMed ID: 337903 [TBL] [Abstract][Full Text] [Related]
48. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. Papp KA; Gooderham MJ; Girard G; Raman M; Strout V J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418 [TBL] [Abstract][Full Text] [Related]
49. Low-dose cyclosporine effective in severe psoriasis: a double-blind study. Heule F; Meinardi MM; van Joost T; Bos JD Transplant Proc; 1988 Jun; 20(3 Suppl 4):32-41. PubMed ID: 3289211 [No Abstract] [Full Text] [Related]
50. [Immunosuppressive agents in the treatment of psoriasis]. Ruszczak Z Vestn Dermatol Venerol; 1976 Jan; (1):35-40. PubMed ID: 997862 [No Abstract] [Full Text] [Related]
51. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. Dogra S; Jain A; Kanwar AJ J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e305-11. PubMed ID: 22816881 [TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. Bissonnette R; Papp K; Maari C; Yao Y; Robbie G; White WI; Le C; White B J Am Acad Dermatol; 2010 Mar; 62(3):427-36. PubMed ID: 20159310 [TBL] [Abstract][Full Text] [Related]
53. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Pariser DM; Pariser RJ; Breneman D; Lebwohl M; Kalb R; Moore J; Moss H; Parker C; Fiedler V Arch Dermatol; 1996 Dec; 132(12):1527. PubMed ID: 8961897 [No Abstract] [Full Text] [Related]
54. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Kragballe K; Jansén CT; Geiger JM; Bjerke JR; Falk ES; Gip L; Hjorth N; Lauharanta J; Mork NJ; Reunala T Acta Derm Venereol; 1989; 69(1):35-40. PubMed ID: 2563606 [TBL] [Abstract][Full Text] [Related]
55. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol; 1996 Apr; 132(4):419-23. PubMed ID: 8629845 [TBL] [Abstract][Full Text] [Related]
56. Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily. Fredriksson T; Lassus A; Bleeker J Br J Dermatol; 1980 May; 102(5):575-7. PubMed ID: 6992844 [TBL] [Abstract][Full Text] [Related]
58. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703 [TBL] [Abstract][Full Text] [Related]
59. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. Omland SH; Habicht A; Damsbo P; Wilms J; Johansen B; Gniadecki R J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1161-1167. PubMed ID: 28107559 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. Cai L; Gu J; Zheng J; Zheng M; Wang G; Xi LY; Hao F; Liu XM; Sun QN; Wang Y; Lai W; Fang H; Tu YT; Sun Q; Chen J; Gao XH; Gu Y; Teixeira HD; Zhang JZ; Okun MM J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):89-95. PubMed ID: 27504914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]